W
WAVEMAN · COMPANY
HRGN · Harvard Apparatus Regenerative Technology, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

HRGN

Harvard Apparatus Regenerative Technology, Inc.
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001563665
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+63.7%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+63.7% year over year
more than 91% of Medical Devices
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 4.3 days to cover · settled 2026-07-31
the lowest in Medical Devices
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +38.2%
+38.2%12M
-41%-15%+12%+38%2025-092025-102025-122026-032026-052026-072026-09 2025-09-02 · He Junli bought $20.8K2025-11-25 · He Junli bought $5.1K2025-09-30 · He Junli bought $594
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
Every figure on this page is a federal filing, dated the day it became public — so you can test what was knowable, not what is known now.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Harvard Apparatus Regenerative Technology, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
He Junli
CEO
BUY
2025-11-25
3,000.0
$5.1K
He Junli
CEO
BUY
2025-09-30
300.0
$594
He Junli
CEO
BUY
2025-09-02
11,225.0
$20.8K
He Junli
CEO
BUY
2025-08-21
4,050.0
$7.0K
He Junli
CEO
BUY
2024-12-24
2,299.0
$6.6K
14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
What changed recently
Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requir
2026-09-04 · Completion moved 2026-07 → 2029-05-18
Phase 1
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Mr. Junli (Jerry) He
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$440.0K
$365.1K
$208.7K
-67%
2024
$1.3M
$894.5K
$246.3K
-46%
2023
$5.8M
$5.8M
$233.4K
-9%
2022
$37.2K
-$10
$227.5K
+174%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$704.0K$430.0K$103.0K
OPERATING INCOME$-6.9M$-7.7M$-9.0M$-6.2M
NET INCOME$-6.9M$-7.7M$-9.0M$-6.1M
EPS (DILUTED)-0.67-0.55
OPERATING CASH FLOW$-3.8M$-4.9M$-6.9M$-5.1M
CASH$1.4M$2.5M$432.0K$1.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →